Detalhe da pesquisa
1.
Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.
Ann Oncol
; 22(2): 341-7, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20693298
2.
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Gynecol Oncol
; 122(1): 107-10, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21463887
3.
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Gynecol Oncol
; 118(3): 308-12, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20646751
4.
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
J Natl Cancer Inst
; 92(9): 699-708, 2000 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-10793106
5.
Prognostic factors in metastatic breast cancer treated with combination chemotherapy.
Cancer Res
; 39(5): 1552-62, 1979 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-427797
6.
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
J Clin Oncol
; 12(1): 60-3, 1994 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-8270985
7.
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
J Clin Oncol
; 11(6): 1156-64, 1993 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-8501502
8.
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol
; 10(5): 718-26, 1992 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-1569444
9.
Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy.
J Clin Oncol
; 10(10): 1561-8, 1992 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-1403035
10.
Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy.
J Clin Oncol
; 21(18): 3495-501, 2003 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12972526
11.
Multivariate analysis of prognostic factors in metastatic breast cancer.
J Clin Oncol
; 1(12): 776-86, 1983 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-6668494
12.
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
J Clin Oncol
; 19(20): 4048-53, 2001 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11600606
13.
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
J Clin Oncol
; 12(12): 2654-66, 1994 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-7989941
14.
Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.
Cancer Treat Rev
; 19 Suppl C: 79-86, 1993.
Artigo
em Inglês
| MEDLINE | ID: mdl-8106156
15.
Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee.
Semin Oncol
; 19(1 Suppl 2): 114-9, 1992 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-1411622
16.
Modeling toxicity and response in carboplatin-based combination chemotherapy.
Semin Oncol
; 21(5 Suppl 12): 7-19, 1994 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-7992070
17.
Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy.
Obstet Gynecol
; 71(3 Pt 1): 327-32, 1988 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-3347416
18.
Ovarian carcinoma: a multivariate analysis of prognostic factors.
Obstet Gynecol
; 65(2): 264-70, 1985 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-3969240
19.
A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity.
Int J Gynecol Cancer
; 2(1): 35-40, 1992 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11576232
20.
Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade).
Int J Gynecol Cancer
; 5(2): 134-142, 1995 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11578468